Skip to main content
    K

    Kalvista Pharmaceuticals Inc (KALV)

    Official site

    BIOTECHNOLOGY

    $27.00
    +0.00 (+0.00%)

    Last updated: Jun 12, 2026 at 5:00 PM ET

    Kalvista Pharmaceuticals Inc (KALV) Financials: Revenue, Profit and Cash Flow

    Updated May 15, 2026. Financial statements from company filings, amounts in US dollars.

    Kalvista Pharmaceuticals reported revenue of $73.62M for the fiscal year ended Apr 30, 2026. That year, net income was -$164.29M with a net margin of -223.2%, operating cash flow was -$81.62M and free cash flow was -$83.33M. The quarter ended Apr 30, 2026 had revenue of $59.92M and net income of -$5.37M.

    Revenue and Margins

    Over the 9 years to Apr 2026, revenue grew from $1.50M, a compound annual rate of 54.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Apr 2026$73.62MN/A91.7%-233.4%-223.2%
    Apr 2025$0N/AN/AN/AN/A
    Apr 2024$0N/AN/AN/AN/A
    Apr 2023$0N/AN/AN/AN/A
    Apr 2022$0-100.0%N/AN/AN/A
    Apr 2021$12.69M0.0%-325.3%-456.4%-364.4%
    Apr 2020$12.69M-21.3%-216.7%-319.4%-229.4%
    Apr 2019$16.13M+92.1%99.8%-184.9%-129.1%
    Apr 2018$8.39M+458.1%99.8%-222.8%-188.3%
    Apr 2017$1.50MN/A99.2%-1485.3%-1236.9%
    Annual, fiscal years ended Apr 2017 to Apr 2026

    Income Statement

    In the fiscal year ended Apr 2026, the net loss narrowed from the year before. In the quarter ended Apr 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemApr 2026Apr 2025Apr 2024Apr 2023Apr 2022Apr 2021Apr 2020Apr 2019Apr 2018Apr 2017
    Revenue$73.62M$0$0$0$0$12.69M$12.69M$16.13M$8.39M$1.50M
    Cost of revenue$6.08M$941.00K$86.17M$802.00K$743.00K$41.29M$40.19M$35.02K$18.24K$12.67K
    Gross profit$67.54M-$941.00K-$86.17M-$802.00K-$743.00K-$41.29M-$27.50M$16.09M$8.38M$1.49M
    Research and development$55.64M$71.71M$86.17M$80.28M$70.17M$41.29M$40.19M$35.02M$18.24M$12.67M
    Operating income-$171.84M-$188.00M-$140.44M-$110.87M-$96.61M-$57.92M-$40.53M-$29.82M-$18.70M-$22.34M
    Net income-$164.29M-$183.44M-$126.64M-$92.91M-$82.34M-$46.24M-$29.12M-$20.82M-$15.80M-$18.60M
    EBITDA-$150.62M-$173.33M-$134.28M-$94.37M-$80.75M-$57.39M-$40.02M-$29.44M-$18.52M-$22.30M
    Fiscal years ended Apr 2017 to Apr 2026

    Quarterly

    Line itemApr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023Jul 2023
    Revenue$59.92M$40.86M$40.86M$1.43M$0$0$0$0$1.21M$0$0$0
    Gross profit$55.95M$37.77M$37.42M$836.00K-$15.89MN/AN/A-$224.00K-$25.25M-$207.00K-$19.09M-$19.31M
    Operating income-$11.51M-$23.44M-$23.44M-$59.01M-$55.03M-$42.94M-$45.81M-$44.22M-$48.45M-$33.15M-$29.75M-$29.09M
    Net income-$5.37M-$23.49M-$23.49M-$60.10M-$52.23M-$48.51M-$42.27M-$40.44M-$44.65M-$29.03M-$27.65M-$25.32M
    Last 12 quarters

    Balance Sheet

    As of Apr 2026, cash and equivalents exceeded total debt of $140.85M by $88.49M. Shareholder equity was negative, at -$2.71M, as total liabilities of $338.09M exceeded total assets of $335.38M.

    Annual

    Line itemApr 2026Apr 2025Apr 2024Apr 2023Apr 2022Apr 2021Apr 2020Apr 2019Apr 2018Apr 2017
    Total assets$335.38M$250.77M$235.40M$183.20M$203.88M$272.01M$92.53M$118.13M$61.39M$34.34M
    Current assets$320.15M$241.69M$225.69M$172.33M$193.65M$264.26M$88.70M$115.55M$59.38M$34.25M
    Cash and equivalents$229.34M$98.64M$31.79M$56.24M$30.73M$50.59M$15.79M$32.01M$51.05M$30.95M
    Total liabilities$338.09M$155.38M$28.82M$22.18M$18.79M$14.82M$8.78M$21.39M$34.14M$3.02M
    Short-term debt$1.62M$1.98M$1.30M$1.09M$977.00K$863.00K$588.00K$54.00K$221.00KN/A
    Long-term debt$139.23MN/AN/AN/AN/AN/AN/AN/A$58.00K$0
    Shareholder equity-$2.71M$95.39M$206.58M$161.03M$185.09M$257.19M$83.75M$96.74M$27.25M$31.33M
    Fiscal years ended Apr 2017 to Apr 2026

    Quarterly

    Line itemApr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023Jul 2023
    Total assets$335.38M$328.92M$335.38M$215.50M$250.77M$275.99M$160.83M$200.20M$235.40M$113.97M$138.74M$160.33M
    Total liabilities$338.09M$348.57M$338.09M$174.72M$155.38M$130.87M$26.84M$27.40M$28.82M$25.39M$24.30M$21.00M
    Cash and equivalents$229.34M$213.77M$229.34M$124.30M$98.64M$167.29M$41.58M$31.85M$31.79M$23.06M$57.67M$49.41M
    Shareholder equity-$2.71M-$19.65M-$2.71M$40.79M$95.39M$145.13M$133.99M$172.80M$206.58M$88.58M$114.45M$139.34M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Apr 2026.

    Annual

    Line itemApr 2026Apr 2025Apr 2024Apr 2023Apr 2022Apr 2021Apr 2020Apr 2019Apr 2018Apr 2017
    Operating cash flow-$81.62M-$152.91M-$89.23M-$75.26M-$78.13M-$30.17M-$44.82M-$36.37M$10.56M-$23.72M
    Capital expenditures$1.71M$434.00K$443.00K$1.20M$931.00K$82.00K$220.00K$1.08M$1.43M$74.00K
    Free cash flow-$83.33M-$153.34M-$89.67M-$76.46M-$79.06M-$30.25M-$45.04M-$37.45M$9.13M-$23.80M
    Investing cash flow$18.68M$91.02M-$84.72M$41.41M$57.86M-$147.65M$16.75M-$69.42M-$1.43M$34.06M
    Financing cash flow$162.64M$159.73M$150.71M$58.12M$1.58M$212.12M$11.58M$87.94M$8.99M$2.00K
    Fiscal years ended Apr 2017 to Apr 2026

    Quarterly

    Line itemApr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023Jul 2023
    Operating cash flow$45.36M-$14.46M-$14.46M-$54.50M-$40.36M-$32.68M-$39.64M-$40.22M-$15.11M-$27.57M-$19.82M-$26.73M
    Capital expenditures$156.00K$203.00K$121.00K$290.00K$350.00K$127.00K$108.00K$21.00K$122.00K$19.00K$2.00K$6.00K
    Free cash flow$45.21M-$14.66M-$14.58M-$54.79M-$40.71M-$32.81M-$39.75M-$40.24M-$15.23M-$27.59M-$19.83M-$26.74M
    Last 12 quarters

    Frequently Asked Questions About KALV

    What is Kalvista Pharmaceuticals' annual revenue?

    Kalvista Pharmaceuticals reported revenue of $73.62M for the fiscal year ended Apr 30, 2026.

    Is Kalvista Pharmaceuticals profitable?

    No. Kalvista Pharmaceuticals reported net income of -$164.29M for the fiscal year ended Apr 30, 2026, with a net margin of -223.2%.

    How much free cash flow does KALV generate?

    For the fiscal year ended Apr 30, 2026, operating cash flow of -$81.62M minus capital expenditures of $1.71M produced free cash flow of -$83.33M.

    How much debt does Kalvista Pharmaceuticals have?

    The balance sheet dated Apr 30, 2026 reported long-term debt of $139.23M, short-term debt of $1.62M and cash and equivalents of $229.34M.

    What is KALV's profit margin?

    For the fiscal year ended Apr 30, 2026, Kalvista Pharmaceuticals reported gross margin of 91.7%, operating margin of -233.4% and net margin of -223.2%.